Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This trial will test the hypothesis that the administration of CF101, a novel
anti-inflammatory agent, to patients with rheumatoid arthritis and high A3AR expression at
baseline will relieve signs and symptoms of the disease.